Transcode Therapeutics Stock Technical Analysis

RNAZ Stock  USD 10.38  0.14  1.33%   
As of the 11th of February 2026, Transcode Therapeutics has the Risk Adjusted Performance of 0.0521, coefficient of variation of 1848.31, and Semi Deviation of 4.61. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Transcode Therapeutics, as well as the relationship between them.

Transcode Therapeutics Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Transcode, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to TranscodeTranscode Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Transcode Therapeutics Analyst Consensus

Target PriceConsensus# of Analysts
10.0Buy1Odds
Transcode Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Transcode analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Transcode stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Transcode Therapeutics, talking to its executives and customers, or listening to Transcode conference calls.
Transcode Analyst Advice Details
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Transcode Therapeutics. Anticipated expansion of Transcode directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Transcode Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(236.52)
Return On Assets
(2.33)
Return On Equity
(17.63)
The market value of Transcode Therapeutics is measured differently than its book value, which is the value of Transcode that is recorded on the company's balance sheet. Investors also form their own opinion of Transcode Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Transcode Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Transcode Therapeutics' market value can be influenced by many factors that don't directly affect Transcode Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Transcode Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Transcode Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Transcode Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Transcode Therapeutics 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Transcode Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Transcode Therapeutics.
0.00
11/13/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/11/2026
0.00
If you would invest  0.00  in Transcode Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Transcode Therapeutics or generate 0.0% return on investment in Transcode Therapeutics over 90 days. Transcode Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and... More

Transcode Therapeutics Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Transcode Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Transcode Therapeutics upside and downside potential and time the market with a certain degree of confidence.

Transcode Therapeutics Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Transcode Therapeutics' standard deviation. In reality, there are many statistical measures that can use Transcode Therapeutics historical prices to predict the future Transcode Therapeutics' volatility.
Hype
Prediction
LowEstimatedHigh
3.0710.1717.27
Details
Intrinsic
Valuation
LowRealHigh
2.049.1416.24
Details
1 Analysts
Consensus
LowTargetHigh
9.1010.0011.10
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Transcode Therapeutics. Your research has to be compared to or analyzed against Transcode Therapeutics' peers to derive any actionable benefits. When done correctly, Transcode Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Transcode Therapeutics.

Transcode Therapeutics February 11, 2026 Technical Indicators

Transcode Therapeutics Backtested Returns

Transcode Therapeutics appears to be moderately volatile, given 3 months investment horizon. Transcode Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0821, which indicates the firm had a 0.0821 % return per unit of risk over the last 3 months. By inspecting Transcode Therapeutics' technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please review Transcode Therapeutics' Semi Deviation of 4.61, risk adjusted performance of 0.0521, and Coefficient Of Variation of 1848.31 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Transcode Therapeutics holds a performance score of 6. The entity has a beta of 0.1, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Transcode Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Transcode Therapeutics is expected to be smaller as well. Please check Transcode Therapeutics' total risk alpha, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Transcode Therapeutics' existing price patterns will revert.

Auto-correlation

    
  -0.09  

Very weak reverse predictability

Transcode Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Transcode Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Transcode Therapeutics price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Transcode Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient-0.09
Spearman Rank Test-0.54
Residual Average0.0
Price Variance2.14
Transcode Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Transcode Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Transcode Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Transcode Therapeutics Technical Analysis

Indicator
Time Period
Execute Indicator
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Transcode Therapeutics across different markets.

About Transcode Therapeutics Technical Analysis

The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Transcode Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Transcode Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Transcode Therapeutics price pattern first instead of the macroeconomic environment surrounding Transcode Therapeutics. By analyzing Transcode Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Transcode Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Transcode Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.

Transcode Therapeutics February 11, 2026 Technical Indicators

Most technical analysis of Transcode help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Transcode from various momentum indicators to cycle indicators. When you analyze Transcode charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Transcode Therapeutics February 11, 2026 Daily Trend Indicators

Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Transcode stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.